Get the Stockscreener App
38.79
1.70%
0.65
Immunovant Inc stock is traded at $38.79, with a volume of 1.05M.
It is up +1.70% in the last 24 hours and up +25.45% over the past month.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates.
See More
Previous Close:
$38.14
Open:
$38.48
24h Volume:
1.05M
Relative Volume:
0.55
Market Cap:
$7.96B
Revenue:
-
Net Income/Loss:
$-505.61M
P/E Ratio:
-14.01
EPS:
-2.7697
Net Cash Flow:
$-407.32M
1W Performance:
+1.44%
1M Performance:
+25.45%
6M Performance:
+49.71%
1Y Performance:
+130.76%
1-Day Range:
$37.75
$38.85
1-Week Range:
$37.51
$39.28
52-Week Range:
$14.32
$39.28
Immunovant Inc Stock (IMVT) Company Profile
Name
Immunovant Inc
Sector
Industry
Phone
917-410-3120
Address
1000 PARK FORTY PLAZA, DURHAM, NY
Compare IMVT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
38.79 | 7.91B | 0 | -505.61M | -407.32M | -2.7697 |
VRTX
Vertex Pharmaceuticals Inc
|
528.04 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
654.27 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
939.68 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.78 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.24 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Mkt Perform |
| Jan-06-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-14-25 | Initiated | Truist | Hold |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Mar-03-25 | Initiated | Jefferies | Hold |
| Jan-03-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Oct-09-24 | Reiterated | Oppenheimer | Outperform |
| Mar-28-24 | Initiated | Oppenheimer | Outperform |
| Mar-13-24 | Initiated | Goldman | Buy |
| Feb-20-24 | Initiated | JP Morgan | Overweight |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-13-23 | Upgrade | UBS | Neutral → Buy |
| Sep-26-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-01-23 | Initiated | BofA Securities | Buy |
| Apr-25-23 | Initiated | Citigroup | Buy |
| Mar-31-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Feb-15-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-13-23 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-03-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-26-22 | Downgrade | UBS | Buy → Neutral |
| Dec-08-21 | Initiated | Wells Fargo | Equal Weight |
| Aug-03-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Aug-02-21 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jun-01-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-21 | Downgrade | Stifel | Buy → Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Oct-12-20 | Initiated | Guggenheim | Buy |
| Oct-08-20 | Initiated | Stifel | Buy |
| Oct-02-20 | Initiated | Credit Suisse | Outperform |
| Aug-26-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Jul-29-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | SVB Leerink | Outperform |
View All
Immunovant Inc Stock (IMVT) Latest News
Immunovant Insider Sold Shares Worth $1,532,309, According to a Recent SEC Filing - Moomoo
Immunovant COO Melanie Gloria sells $678k in company stock By Investing.com - Investing.com India
Form 144 IMMUNOVANT For: 26 June By Investing.com - Investing.com South Africa
Insider Sell: Melanie Gloria Sells 17,714 Shares of Immunovant I - GuruFocus
Form 4 Immunovant Inc For: 26 June By Investing.com - Investing.com Nigeria
Avoiding Lag: Real-Time Signals in (IMVT) Movement - Stock Traders Daily
Immunovant CTO Jay Stout sells $1.53m in company stock By Investing.com - Investing.com Australia
Immunovant CFO Tiago Girao sells $384,600 in company stock By Investing.com - Investing.com Australia
Immunovant chief legal officer sells $682,886 in stock - Investing.com
Immunovant (IMVT) CFO exercises options, sells 10,000 shares at ~$38 average - Stock Titan
Immunovant chief legal officer sells $682,886 in stock By Investing.com - Investing.com South Africa
Immunovant director Atul Pande sells $57,015 in stock By Investing.com - Investing.com Canada
Immunovant (IMVT) COO sells 17,714 shares, keeps 224,393 stake - Stock Titan
Immunovant (IMVT) CTO Jay S. Stout sells 40,000 shares in open-market trades - Stock Titan
Immunovant (IMVT) Chief Legal Officer sells 17,824 shares after option exercise - Stock Titan
Immunovant (IMVT) director sells 1,500 shares after option exercise - Stock Titan
Insider Sale: President & Immunovant CEO of $ROIV Sells 46,234 Shares - Quiver Quantitative
IMVT (NASDAQ) Form 144 lists multiple vested restricted stock blocks, 40,000 header - Stock Titan
IMVT (NASDAQ: IMVT) files Form 144 for 17,824-share sale after option exercise - Stock Titan
[144] Immunovant, Inc. SEC Filing - Stock Titan
Immunovant Inc Actuals & Estimates (NASDAQ:IMVT) - TradingView
Price to book forward of Immunovant, Inc. – NASDAQ:IMVT - TradingView
Price to sales forward of Immunovant, Inc. – NASDAQ:IMVT - TradingView
Enterprise value to EBITDA forward of Immunovant, Inc. – NASDAQ:IMVT - TradingView
IMVT Forecast — Price Target — Prediction for 2027 - TradingView
Immunovant (IMVT) up 3.6% since last earnings report: Can it continue? - MSN
Immunovant (IMVT) CLO mandated share sale to cover RSU tax withholding - Stock Titan
Immunovant stock hits 52-week high at 36.39 USD By Investing.com - Investing.com Australia
Cutaneous Lupus Erythematosus Market to Expand at a CAGR of 8% During the Forecast Period (2026–2036) Amid Emerging Therapies and Increasing Healthcare Investments | DelveInsight - GlobeNewswire Inc.
Immunovant stock hits 52-week high at 36.39 USD - Investing.com
Immunovant Stockweekly view after recent volatility - Ad-hoc-news.de
Immunovant stock gains 12.4% in a month: What's driving it? - MSN
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Immunovant Inc (IMVT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immunovant Inc (IMVT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immunovant Inc (IMVT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immunovant Inc (IMVT) Institutional Confidence - TradingKey
Immunovant Inc (IMVT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immunovant Inc (IMVT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immunovant Inc (IMVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immunovant Inc (IMVT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immunovant Inc (IMVT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
IMVT's Q4 loss wider than expected, stock up 35% on strong study data - MSN
Immunovant (IMVT) director trades 1,500 shares under 10b5-1 plan - Stock Titan
Discipline and Rules-Based Execution in IMVT Response - Stock Traders Daily
IMVT (NASDAQ: IMVT) files Form 144 reporting 6,000-share option exercise sale - Stock Titan
Immunovant Q4 earnings call highlights - MSN
Immunovant Stock Gains 12.4% in a Month: What's Driving It? - The Globe and Mail
Immunovant Inc Stock (IMVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunovant Inc Stock (IMVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Stout Jay S | Chief Technology Officer |
Jun 26 '26 |
Sale |
38.31 |
40,000 |
1,532,309 |
211,685 |
| Van Tuyl Christopher | Chief Legal Officer |
Jun 26 '26 |
Option Exercise |
15.20 |
17,824 |
270,925 |
198,421 |
| Van Tuyl Christopher | Chief Legal Officer |
Jun 26 '26 |
Sale |
38.31 |
17,824 |
682,887 |
180,597 |
| Girao Tiago | Chief Financial Officer |
Jun 26 '26 |
Option Exercise |
15.90 |
10,000 |
159,000 |
257,596 |
| Girao Tiago | Chief Financial Officer |
Jun 26 '26 |
Sale |
38.46 |
10,000 |
384,600 |
247,596 |
| Pande Atul | Director |
Jun 26 '26 |
Option Exercise |
8.43 |
1,500 |
12,645 |
118,231 |
| Pande Atul | Director |
Jun 26 '26 |
Sale |
38.01 |
1,500 |
57,015 |
116,731 |
3.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):